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Abstract
Background: Antibodies to the myelin oligodendrocyte glycoprotein (MOG) are associated with a subset of
inflammatory demyelinating diseases of the central nervous system such as acute disseminated encephalomyelitis
and neuromyelitis optica spectrum disorders. However, whether human MOG antibodies are pathogenic or an
epiphenomenon is still not completely clear. Although MOG is highly conserved within mammals, previous
findings showed that not all human MOG antibodies bind to rodent MOG. We therefore hypothesized that
human MOG antibody-mediated pathology in animal models may only be evident using species-specific MOG
antibodies.
Methods: We screened 80 human MOG antibody-positive samples for their reactivity to mouse and rat MOG
using either a live cell-based assay or immunohistochemistry on murine, rat, and human brain tissue. Selected
samples reactive to either human MOG or rodent MOG were subsequently tested for their ability to induce
complement-mediated damage in murine organotypic brain slices or enhance demyelination in an experimental
autoimmune encephalitis (EAE) model in Lewis rats. The MOG monoclonal antibody 8-18-C5 was used as a
positive control.
Results: Overall, we found that only a subset of human MOG antibodies are reactive to mouse (48/80, 60%)
or rat (14/80, 18%) MOG. Purified serum antibodies from 10 human MOG antibody-positive patients (8/10 reactive to
mouse MOG, 6/10 reactive to rat MOG), 3 human MOG-negative patients, and 3 healthy controls were tested on murine
organotypic brain slices. Purified IgG from one patient with high titers of anti-human, mouse, and rat MOG antibodies
and robust binding to myelin tissue produced significant, complement-mediated myelin loss in organotypic brain slices,
but not in the EAE model. Monoclonal 8-18-C5 MOG antibody caused complement-mediated demyelination in both the
organotypic brain slice model and in EAE.
Conclusion: This study shows that a subset of human MOG antibodies can induce complement-dependent pathogenic
effects in a murine ex vivo animal model. Moreover, a high titer of species-specific MOG antibodies may be critical
for demyelinating effects in mouse and rat animal models. Therefore, both the reactivity and titer of human
MOG antibodies must be considered for future pathogenicity studies.
Keywords: Myelin oligodendrocyte glycoprotein, MOG, Antibodies, Organotypic slice culture, EAE,
Neuromyelitis optica spectrum disorders
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Background
In the last decades, several studies reported that autoanti-
bodies against the myelin oligodendrocyte glycoprotein
(MOG) are associated with inflammatory demyelinating
diseases of the central nervous system (CNS), such as
acute disseminated encephalomyelitis (ADEM), mono-
phasic or recurrent isolated optic neuritis (ON) or trans-
verse myelitis (TM), pediatric multiple sclerosis (MS),
aquaporin-4 (AQP4)-seronegative neuromyelitis optica
spectrum disorders (NMOSD), and N-methyl D aspartate
receptor (NMDAR) encephalitis with overlapping demye-
linating syndromes [1–16]. Although MOG antibodies are
rarely found in MS, MOG-seropositive patients show
neuropathological features that are similar to MS pattern
II pathology with demyelinated lesions, preserved axons
and complement-mediated pathology [17–20]. MOG is a
very well-studied antigen in experimental autoimmune
encephalomyelitis (EAE), which is often used as a model
for MS. These animal models have been developed using
active immunization with MOG, transfer of MOG-specific
T cells and antibodies, and mice transgenic for MOG-
specific T and B cell receptors [21–27]. In EAE, it was
demonstrated that MOG antibodies are strongly patho-
genic only after inflammation and blood-brain barrier
leakage induced by encephalitogenic T cells. Co-transfer
of the mouse monoclonal anti-MOG antibody 8-18-C5
leads to severe complement-dependent lesions in a myelin
basic protein (MBP)-induced EAE model in Lewis rats
[21, 22, 28] and in vitro brain cell cultures [29].
Nevertheless, the effects of human MOG (hMOG)
antibodies and their exact role in demyelinating diseases
are still not fully understood. While hMOG antibodies
can initiate both complement-dependent cytotoxicity
(CDC) and antibody-dependent cellular cytotoxicity
(ADCC) in an Fc-dependent manner [30–34], in vitro
studies have demonstrated MOG antibody binding
causes disturbances of thin filaments and microtubule
cytoskeleton in oligodendrocytes [35] and cellular
cytotoxic effects [2] independent of effector function.
Previous in vivo studies have indicated that MOG
antibodies trigger the activation of MOG-specific T
cells by facilitating opsonization and accumulation in
antigen-presenting cells in the CNS and periphery.
This process then fosters T cells to recognize their auto-
antigen and activate in an Fc-dependent manner [36, 37].
Administration of hMOG antibodies into a MBP-T cell-
mediated EAE model in Lewis rats resulted in minor
demyelination and axonal loss in the absence of exces-
sive complement activation [38], and intracerebral in-
jection of hMOG-IgG into murine brain resulted in
complement-independent reversible demyelination and
axonal loss [39].
It has become increasingly clear that only MOG anti-
bodies recognizing correctly folded and glycosylated
MOG are disease relevant. Although MOG is highly
conserved between different species, previous studies
have shown that single amino acid exchanges between
mouse MOG (mMOG) and hMOG led to a loss of bind-
ing ability of most hMOG antibodies to mMOG [40].
These experimental observations and the polyclonal na-
ture of serum IgG reinforce that not all hMOG autoanti-
bodies will be reactive to rodent MOG [40, 41]. To
our knowledge, these species-specific recognition pat-
terns have not been systematically evaluated when
analyzing the pathogenicity of human MOG anti-
bodies. Therefore, our study aimed to investigate
whether hMOG autoantibodies carefully selected for
binding to both hMOG and rodent MOG can induce
demyelinating pathology in rodents. We screened
hMOG-reactive patient sera for reactivity to mMOG
and rat MOG (rMOG), analyzed binding patterns in
different brain tissues, and selected a set of high and
low titer IgG samples with different binding patterns
to rodent MOG to perform ex vivo and in vivo stud-
ies for demyelinating activity.
Methods
Patients
Serum samples were collected at the Clinical Depart-
ment of Neurology, Medical University of Innsbruck be-
tween 2008 and 2016 and stored at − 80 °C until use.
This study was approved by the Ethical Committee of
the Medical University of Innsbruck (study numbers
AM3041A and AM4059) and by the Ethic Committees
of the Hospital Clinic of Barcelona (2010/5680), Charite
University Medicine Berlin (EA1/131/09), and University
Hospital Zürich (KEK-Nr. 2013-0001). All patients or
their caregivers gave informed written consent.
Serum samples were collected from 80 hMOG anti-
body positive, 20 hMOG antibody negative individuals,
and 4 healthy controls: 48 ADEM patients, 4 multiphasic
demyelinating encephalomyelitis (MDEM) patients, 13
NMOSD patients, 21 patients with clinically isolated
syndrome (CIS; 13 ON, 6 myelitis and 2 multifocal), 7
recurrent ON patients, and 7 MS patients (Table 1).
NMOSD was diagnosed by the 2015 International Panel
for NMO Diagnosis Criteria, ADEM was diagnosed ac-
cording to the criteria of the International Pediatric MS
Study Group, and MS was diagnosed according to the
2010 revised McDonald criteria [42–44].
Animals
Animal experiments on Lewis rats were approved by the
Ethical Committee of the Medical University of Vienna
(BMWF-66.009/0196-WF/V/3b/2015). Rats were ob-
tained from Charles River Wiga (Sulzfeld, Germany) and
housed in the Decentral Facilities of the Institute for
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Biomedical Research, Vienna under standard conditions
until animals reached the age of 7–9 weeks.
Transgenic PLP-EGFP mice were housed in at the
University of Colorado in accordance with University of
Colorado IACUC policy for animal use, which is in com-
pliance with the NIH Guide for the Care and Use of La-
boratory Animals. Pups aged P10–P12 were used for
cerebellar slice cultures.
Screening for serum reactivity to human, mouse, and rat
MOG on a live cell-based assay
One hundred samples were analyzed for antibodies
against hMOG, rMOG, and mMOG by a live cell-based
assay (CBA) as described previously [6, 45]. Briefly,
HEK-293A cells (ATCC, LGC Standards GmbH, Wesel,
Germany) were transiently transfected with Fugene HD
transfection reagent (Promega Corporation, Madison,
Table 1 Demographic and clinical data and antibody reactivity of patients included in this study according to the human MOG
antibody status
hMOG antibody negativea hMOG antibody positivea P value
Number of patients/samples 20 80
hMOG antibody titer [1:]b 1280 (160–20,480)
Females 9 (45%) 37 (46%) 0.999c
Age (years)b 12.4 (3.5–44.8) 7.0 (0.2–71.1) 0.020d
Pediatric patients 15 (75%) 69 (83%) 0.303c
Disease duration (years)b 0.3 (0–19.7) 0.1 (0–15.4) 0.038d
Clinical diagnosis at sampling:
ADEM 11 (55%) 37 (46%) < 0.001e
CIS-ON 0 (0%) 13 (16%)
CIS-LETM 1 (5%) 5 (6%)
CIS-multifocal 0 (0%) 2 (3%)
MDEM 0 (0%) 4 (5%)
NMOSD 1 (5%) 12 (15%)
Recurrent ON 0 (0%) 7 (9%)
MS 7 (35%) 0 (0%)
Recurrent course at sampling 7 (35%) 17 (21%) 0.243c
Reactive with mouse MOGa 0 (0%) 48 (60%) < 0.001c
Median titer (range) 640 (160–20,480)
Reactive with rat MOGa 0 (0%) 14 (18%) 0.066c
Median titer (range) 1280 (160–5120)
Reactivity with brain tissue:
Antibody binding to human myelin 0 (0%) 70 (88%) < 0.001c
Antibody binding to mouse myelin 1 (5%) 27 (34%) 0.011c
Thereof mMOG reactive 0/1 (0%) 25/27 (93%)
Thereof rMOG reactive 0/1 (0%) 11/27 (41%)
Therof mMOG or rMOG reactive 0/1 (0%) 25/27 (93%)
Antibody binding to rat myelin 4 (20%) 24 (30%) 0.578c
Thereof mMOG reactive 0/4 (0%) 23/24 (96%)
Thereof rMOG reactive 0/4 (0%) 14/24 (58%)
Therof mMOG or rMOG reactive 0/4 (0%) 23/24 (96%)
Abbreviations: hMOG human myelin oligodendrocyte glycoprotein, mMOG mouse MOG, rMOG rat MOG, ADEM acute demyelinating encephalomyelitis, CIS clinically
isolated syndrome, ON optic neuritis, LETM longitudinally extensive transverse myelitis, MDEM multiphasic demyelinating encephalomyelitis, NMOSD neuromyelitis
optica spectrum disorders, MS multiple sclerosis
aPositive for antibodies to hMOG, mMOG, or rMOG at a cutoff ≥ 1:160
bMedian (range). Significance of group differences was calculated using
cFisher’s exact test
dMann-Whitney U test
eChi square test
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WI, USA) using the pEGFP-N1 vector (Clontech La-
boratories, Mountain View, CA, USA) expressing either
hMOG, mMOG, or rMOG fused to EGFP at the C
terminus. Cells were blocked with goat IgG (Sigma-Al-
drich, St. Louis, MO, USA). For pre-screening, samples
were diluted 1:20 and 1:40 in PBS/10%FCS (Sigma-Al-
drich) and incubated for 1 h at 4 °C. Bound antibodies
were detected using Cy™3-conjugated goat anti-human
IgG antibody (H+L, Jackson ImmunoResearch Labora-
tory, West Grove, PA, USA) for 30 min at room
temperature (RT). DAPI staining (Sigma-Aldrich) was
used to exclude dead cells. Cell bound antibodies were
determined using a fluorescence microscope (Leica
DMI, 4000B, Wetzlar, Germany). Seropositivity was eval-
uated by two blinded investigators (PP, KS), and anti-
body titers were determined by endpoint titrations.
Specificity of this assay was tested with hMOG-negative,
AQP4-positive samples, and healthy controls [41]. Non-
specific background binding can be clearly distinguished
from MOG-positive antibody signal.
Immunoglobulin G subclasses were evaluated using
mouse anti-human IgG1, IgG2, IgG3, and IgG4 anti-
bodies (Thermofisher Scientific, Waltham, MA, USA)
and stained with Alexa 594 goat anti mouse IgG (H+L)
(Thermo Fisher Scientific).
Binding capacities of human MOG antibodies to human,
rat, and mouse brain tissue
All serum samples were analyzed for IgG antibodies di-
rected against myelin antigens by immunohistochemistry
(IHC) on mildly fixed, snap-frozen rat, mouse, or human
postmortem brain tissue as described previously [46].
Briefly, human cerebellar autopsy, taken about 24-h
postmortem, or frontal lobe biopsy were mildly fixed in
4% PFA for 1 h at 4 °C and subsequently cryoprotected
using 40% Sucrose/PBS (Merck, Darmstadt, Germany) at
4 °C for 2–3 days. Tissue was imbedded in freezing
medium (O.C.T™, Tissue-Tek®, Sakura, Alphen aan den
Rijn, Netherlands) and snap-frozen in liquid nitrogen
pre-chilled methylbutan (Sigma-Aldrich). Rats and mice
were sacrificed either with CO2 or cervical dislocation,
sagitally sectioned, and treated like human brain tissue.
Rodent and human frozen tissue was sectioned into 7-
μm-thick slices and blocked for 1 h at RT using 5% nor-
mal goat serum (NGS) and 1% bovine serum albumin
(BSA) in 0.05% PBS-Tween. Serum samples were pre-
adsorbed overnight on a shaker with 10 mg/100 μl Calf
Liver Powder (produced in house according to Coons et
al. [47]) in 1%NGS/1%BSA/PBS. Pre-adsorbed serum
was added to the blocked slices in a final dilution of
1:100 in 1%NGS/1%BSA/0.05%Tween/PBS and incu-
bated over night at 4 °C. Bound serum IgG was detected
using Alexa Fluor, 488 conjugated AffiniPure F(ab)2 frag-
ment goat anti human IgG (Jackson ImmunoResearch,
West Grove, PA, USA) in 1%NGS/1%BSA/0.05%Tween/
PBS. Afterwards, slides were mounted with IF media
(Dianova, Hamburg, Germany) and analyzed with a
fluorescence microscope (Leica DMI4000). To deplete
hMOG-specific antibodies, serum IgG was pre-adsorbed
with hMOG-transfected HEK 293 cells.
Production of monoclonal mouse and humanized 8-18-C5
Mouse monoclonal MOG antibodies (isotype IgG2B)
were produced with the 8-18-C5-specific hybridoma cell
line (kindly provided by Christopher Linington, Univer-
sity of Aberdeen, UK) and cultured in Hybridoma-SFM
Medium (Gibco; Thermo Fisher Scientific). Supernatant
was collected and cells split frequently to ensure optimal
growth conditions. Humanized 8-18-C5 was produced
by cloning the coding sequence of the variable region of
mouse 8-18-C5-specific Kappa-light (8-18-C5-vLC) and
heavy F.ab 1 chain (8-18-C5-vHC) (kindly provided by
Klaus Dornmair, LMU, Munich, Germany) into the vec-
tor pFUSE-CHIg-hG1 (encoding the constant region of
the heavy chain) and pFUSE2-CLIg (encoding the con-
stant region of the light chain) (InvivoGen, San Diego,
CA, USA), respectively. Vectors, containing 8-18-C5-
specific heavy and light chains, were transfected simul-
taneously into HEK 293FT cells cultured in Freestyle™
Expression Medium (Gibco, Thermo Fisher scientific),
using Polyethylenimine (PEI) (1 mg/ml, Sigma-Aldrich)
as a transfection agent. Double transfected cells were se-
lected and cultured in growth medium containing Blasti-
cidin (10 μg/ml, Gibco, Thermo Fisher scientific), for
pFUSE2-CLIg and Zeocin (400 μg/ml, Invitrogen,
Thermo Fisher scientific), for pFUSE-CHIg-hG1. Super-
natant was collected and cells split frequently to ensure
optimal growth conditions.
Antibody purification
Human antibodies from sera and therapeutic plasma ex-
change material as well as monoclonal 8-18-C5 were puri-
fied using Protein G Sepharose (GE Healthcare, Munich,
Germany) beads and adjusted to a concentration of 5 and
10 mg/ml with 100 kDa centrifugation filter columns
(Amicon Ultra, Merck, Darmstadt, Germany) for murine
cerebellar slice culture and the EAE injection model, re-
spectively. After sterile filtration, purity was checked by
SDS-PAGE and functionality was tested using the live
cell-based anti-MOG assay.
Ex vivo mouse organotypic cerebellar slice model
Cerebella were dissected from P10-P12 old PLP-EGFP
mice, cut sagittally into 300-μm slices, and cultured on
0.4-μm membrane inserts (Merck Millipore, Billerica,
MA, USA) for 7–9 days in sterile minimum essential
media containing 25% Hank’s balanced salt solution and
25% inactivated horse serum, as described previously
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[48]. Media was changed every 3 days to maintain cul-
ture integrity. Slice integrity was observed by excluding
tissue with necrotic holes and limited folia formation.
Prior to antibody treatment, media was exchanged with
serum-free media (Neurobasal-A media (Life technolo-
gies), enriched with B27, 2 mM L-Glutamine, 2% HEPES,
and 18 mM D-Glucose (Sigma-Aldrich)). Human anti-
bodies were diluted to a final concentration of 1 mg/ml
in serum-free media with or without 10% human sera
containing complement (Complement Technology, Inc.,
Tyler, TX, USA) and slices were subsequently incubated
for 72 h at 37 °C, 5% CO2. Monoclonal 8-18-C5 was
used in a concentration of 10 μg/ml. Each IgG sample
was tested on healthy murine organotypic brain slices in
at least two repetitions and two random cerebellar folia
were imaged by confocal microscopy. Myelin status was
evaluated by a MBP rating scale (median myelin score;
MMS) (0 = healthy myelin with well-preserved myelin
sheaths around myelinated axons; 1 = slight MBP deg-
radation and myelin disruption; 2 = partial myelin loss,
intermediate to severe MBP damage; 3 = almost
complete loss of myelin along myelinated axons and se-
vere MBP loss). Variations within the range of MMS
were caused by unspecific degradation processes during
cultivation of the cerebellar preparations in some of the
slices, which could be diminished by repeated testing
and median calculations.
At the end of the experiment, slices were fixed with
4% PFA in PBS and processed for IHC. Briefly, slices
were permeabilized in 10% Triton X-100 in PBS, blocked
with 5% normal donkey serum (NDS) in 0.3% PBS-
Triton X-100 for 1 h at RT and then incubated with pri-
mary antibodies in blocking solution: mouse anti-MBP
(1:1000) (Covance, Princeton, NJ, USA) and an axonal
marker, either chicken anti-neurofilament (1:10,000)
(Covance) or/and chicken anti-calbindin (1:1000) (Neu-
romics). Following primaries, slices were washed, stained
with secondary antibodies conjugated to Alexa Fluor
(Jackson Immuno), washed with PBS, and mounted with
Fluoromount-G (Southern Biotech, Birmingham, AL,
USA). Due to potential competition between patient and
commercial MOG antibodies, MOG staining was omit-
ted and overall myelin integrity was evaluated using
MBP staining [49, 50].
MOG-IgG EAE
MBP-specific T cells were established as described earlier
[51]. EAE was induced by passive transfer of freshly acti-
vated MBP-T cells (2 × 106) into 7–9-weeks old Lewis
rats. Weight loss and changes in the EAE score [52] in
all animals indicated the first clinical signs of EAE. Four
days post-treatment, animals were injected intraperito-
neally with 5 mg monoclonal 8-18-C5 or isotype control,
10 or 40 mg purified IgG from MOG-positive subjects,
negative control samples and normal human IgG (Sub-
cuvia™) (Baxter, Vienna, Austria). As an additional con-
trol, animals were injected with patient IgG without
prior EAE induction (PBS transfer only). Animals were
sacrificed with CO2 24 or 48 h post injections. Blood
samples were taken by cardiac puncture, and animals were
subsequently perfused with 4% PFA. Spinal cords were
dissected and immersed for another 24 h in PFA and rou-
tinely embedded in paraffin. Tissue sections were stained
with hematoxylin and eosin, Kluver-Barrera (myelin), anti-
MOG, anti-C9neo (complement), anti-CD3 (T cells), and
anti-ED1 (macrophages). Spinal cord sections of the rats
were quantified according to the following score: Demye-
lination score (DMS) 0 = no lesions/slice, DMS 1 = one
minor lesion/slice (0.05–0.2 mm diameter), DMS 2 = two
minor lesions/slice or one medium lesion (> 0.2 mm
diameter), DMS 3 = two or more medium lesions/slice,
and DMS 4 = extensive loss of myelin.
Statistical analysis
Statistical analysis was done using IBM SPSS software
(release 24.0, IBM) or GraphPad Prism 7 (GraphPad).
Between-group comparisons were performed with Mann-
Whitney U test, Friedman test, Fisher’s exact test, and chi-
square test. Statistical significance was defined as two-
sided p value < 0.05, and Bonferroni corrections were ap-
plied for multiple comparisons when appropriate.
Results
Limited human MOG-positive sera react with both murine
and rat MOG in a live cell-based assay
We screened 80 hMOG-positive (titer ≥ 1:160) serum and
plasma exchange samples (median titer 1:1280, range
160–20,480) for IgG-binding to mMOG and rMOG using
a CBA (Table 1, Fig. 1, and Additional file 1). To exclude
non-specific binding the high-titer cutoff value of ≥ 1:160
was applied. Forty-eight samples (60%) were positive for
mMOG and only 14 samples (18%) for rMOG (Table 1
and Fig. 1). Samples positive to rodent MOG were either
reactive to mMOG only (34/48, 71%) or both, mMOG
and rMOG (14/48, 29%); none of them bound to rMOG
only. No significant association between antibody binding
to mMOG or rMOG and clinical diagnosis was observed
(Additional files 2 and 3). Neither the 20 hMOG-negative
controls nor the 4 healthy controls were positive for
rMOG or mMOG at a cutoff ≥ 1:160 (Table 1). Twenty-
seven follow-up samples from 25 patients did not reveal
any change in species-specific reactivity (data not shown).
Immunohistochemistry with human MOG antibodies on
human, mouse, and rat brain tissue is less sensitive than
CBA
We next evaluated the binding of MOG-seropositive
serum samples to rodent and human brain tissue. The
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criterion for positive tissue reactivity was a clear myelin
staining in the white matter tract of the cerebellum, cor-
pus callosum, or internal capsule, clearly distinguishable
from the regular background of healthy controls (Fig. 2).
Only 27/80 hMOG-reactive samples (34%) showed posi-
tive staining on mouse tissue (Table 1). Twenty-five of
them were positive (cutoff ≥ 1:160) for mMOG in the
CBA, and two had only low titers to mMOG (1:40)
(Table 1 and Additional file 2). Similar results were seen
when hMOG-positive samples were tested on rat tissue.
Altogether, 24/80 hMOG-positive samples (30%) showed
a positive staining on rat tissue (Table 1). Fourteen
(58%) of them were reactive to rMOG at a cutoff of
1:160, 4 had low titers to rMOG (1:20–1:80), and 6 were
tested negative for rMOG in the CBA (Table 1 and
Additional file 3). Two samples with no reactivity to ro-
dent MOG bound to mouse tissue and one sample to
rat tissue.
All hMOG antibody-positive samples were also tested
on human brain tissue. Seventy of 80 (88%) samples
stained the white matter tract of human cerebellum and
white matter of a frontal lobe biopsy (Fig. 2a and
Table 1). Their median hMOG titer was 1:1280 (range
160–20,480). However, 10/80 (12%) samples did not
show a positive staining despite their relatively high
hMOG titers (median titer 1:640, range 320–20,480). To
test whether the observed myelin staining was MOG
specific, hMOG antibody-positive samples, used for ex
vivo and in vivo experiments (Table 2), were pre-
adsorbed against hMOG-transfected cells, resulting in a
significant reduction in hMOG titers (data not shown),
and in human and rodent myelin staining (Fig. 2b).
In summary, 7 samples showed no binding to human,
mouse, or rat myelin tissue, 39 samples were reactive
with human myelin tissue only, 1 with rat tissue only, 6
with human and rat tissue, 2 with mouse tissue only, 8
with human and mouse tissue, and 17 with human,
mouse, and rat myelin tissue (Additional file 4). Differ-
ential tissue binding was associated with increased anti-
body titers to hMOG, mMOG, and rMOG, but not with
demographic or clinical parameters (Additional file 4).
As a control for non-specific antibody binding 20
hMOG antibody-negative samples and healthy controls
were included. None of them showed a positive myelin
staining in human tissue. Interestingly, 5/20 (25%) hMOG
antibody-negative controls showed a positive myelin stain-
ing on mouse (1/20, 5%) and rat brain tissue (4/20, 20%)
that was not eliminated by pre-adsorption against MOG-
transfected cells (Table 1).
One MOG antibody-positive sample causes complement-
mediated myelin damage in murine organotypic brain
slices
Ten hMOG-positive samples with sufficient volume for
purification and further analysis were used for analysis
of pathogenicity on organotypic mouse brain slice cul-
tures. Eight of the 10 samples were reactive to mMOG,
and 2 samples had mMOG antibody titers below the
cutoff of 1:160 (1:20, Table 2). Six of the 10 samples were
reactive to rMOG. Five samples were reactive with
mouse, and 6, with rat myelin tissue (Table 2). All sam-
ples were positive for hMOG IgG1 antibodies, whereas
other IgG subclasses were only present at lower titers
(Additional file 5). Sera from three MOG-negative pa-
tients with demyelinating CNS disease and three healthy
control subjects were also included as additional nega-
tive controls (Table 2).
The addition of humanized anti-MOG monoclonal
antibody (mAb) 8-18-C5 to the organotypic slices led to
fulminant myelin disruption and MBP loss with a MMS
of 3 (Fig. 3 and Table 2). Oligodendrocyte death, indi-
cated by loss of PLP-EGFP expression, was not observed
following treatment with mAb 8-18-C5. Axonal integrity
(NF-H staining) was only partially affected by mAb 8-
Fig. 1 Serum antibody titer levels to human, mouse, and rat MOG by live cell-based assay. The cutoff titer value of 1:160 is indicated by a dashed
horizontal line. Individual antibody titers are shown as black circles (reactive to hMOG only), yellow triangles (reactive to hMOG+mMOG) or red
squares (reactive to hMOG+mMOG+rMOG). Antibody titers were compared using a non-parametric test (Friedman’s test with Dunn’s multiple
comparisons test, overall p value < 0.001). ***p < 0.001
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18-C5 exposure, indicated by regional swellings
(Fig. 3). The demyelinating effects were completely
complement-dependent (Fig. 3). In contrast, total IgG
from only one MOG-IgG-seropositive patient (MOG 7)
showed complement-dependent mild pathological effects
with a MMS of 1.5 (Table 2, Fig. 4, Additional file 6). Mye-
lin was partly disrupted along axonal swellings, indicated
by damage and partial loss of MBP (Fig. 4, Add-
itional file 6). Total IgG from this sample demonstrated
the highest titers against hMOG (1:5120), mMOG
(1:5120), and rMOG (1:5120) and bound to human,
mouse, and rat myelin in tissue sections. All other samples
with positive mouse tissue binding patterns (4/9) or re-
activity to mMOG (7/9), as well as healthy or MOG sero-
negative inflammatory controls were negative for
antibody-induced pathology (Table 2).
MOG antibodies show no antibody-mediated pathology
in an MBP-T cell-mediated EAE rat model
We next evaluated two hMOG antibody-positive sam-
ples (MOG 6 and MOG 7) with sufficient amount of
IgG for co-transfers for pathology in an EAE rat model.
MOG 7 was reactive to all tested species and showed a
demyelinating effect in murine organotypic brain slices,
Fig. 2 a Myelin staining with serum from human samples and monoclonal 8-18-C5 on human, mouse, or rat cerebellum. White matter tracts and
folia were clearly stained with MOG antibody-positive serum samples and 8-18-C5 but not in MOG antibody-negative control samples. Sections
were magnified at ×20 (mouse/rat tissue) and at ×10 (human tissue). b Serum samples reactive to human and mouse MOG bind to both human
and mouse cerebellum sections. Pre-adsorbed samples show a significant reduction in MOG-specific myelin staining. Sections were magnified at
×2.5 (human tissue) and at ×20 (mouse tissue). Inlays show higher magnification (10×) of human white matter tracts
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whereas, MOG 6 was reactive to hMOG and mMOG
and showed no pathology on organotypic mouse brain
slices. MOG 6 and another MOG IgG-negative sample
served as negative controls in the rat EAE model. An
additional total IgG sample obtained from a plasma ex-
change sample was added to this study, only reactive to
hMOG (titer 1:2560) and mMOG (1:1280), but not
tested on organotypic brain slices (MOG 11, Table 2).
Mouse anti-MOG monoclonal antibody 8-18-C5 was
used as a positive control. No demyelinating lesions
above background levels (DMS = 1, Table 2 and Fig. 5)
were seen after injection of MBP-specific T cells with or
without MOG 7- or rMOG-negative controls. Further,
no effects were noted at a higher IgG concentration
(40 mg/ml) and/or after a longer interval (48 h) (data
not shown). In contrast, co-transfer of the monoclonal
mouse 8-18-C5 at a concentration of 5 mg/ml caused
lesions with extensive demyelination, macrophage re-
cruitment, and perivascular complement deposition
(DMS = 4, Table 2 and Fig. 6). Following injection, the
presence of antibodies to hMOG and rMOG in rat sera
were verified by CBA. Titers to hMOG were significantly
decreased in rat serum samples compared to original ti-
ters (10 mg/ml animals: median titer 1:160, range 1:80–
320; 40 mg/ml animals: median titer 1:640, range 1:640).
Titers to rMOG were equally low as hMOG titers.
Discussion
Only a limited fraction of human MOG antibodies re-
veal reactivity to either mMOG or rMOG by CBA. Re-
activity to mMOG (60%) was more frequently seen than
rMOG (18%). The present investigation is the largest
study on species-specific reactivity of human MOG anti-
bodies conducted so far, confirming results of prior
Table 2 Samples analyzed on murine organotypic brain slices and in the rat EAE model
CBA Tissue binding Slice culture Rat EAE
Sample ID Sex/age
(years)
Diagnosis hMOG
titer (1:)
rMOG
titer (1:)
mMOG
titer (1:)
Human
tissue
Mouse
tissue
Rat
tissue
Total IgG
used
MMS
(range)
Total IgG
used
DMS
MOG 1 F/4 MDEM 2560 160 2560 + + + 1 mg/ml 0 (0–1) n.a. n.a.
MOG 2 F/7 Rec-ON 2560 160 1280 + − + 1 mg/ml 0 (0–1) n.a. n.a.
MOG 3 F/8 NMOSD 1280 0 160 + − − 1 mg/ml 0 (0–2) n.a. n.a.
MOG 4 F/1 MDEM 2560 0 20 + − − 1 mg/ml 0 (0–1) n.a. n.a.
MOG 5 M/13 Rec-ON 1280 0 20 + − − 1 mg/ml 0 (0) n.a. n.a.
MOG 6 M/53 NMOSD 5120 0 1280 + − − 1 mg/ml 0 (0–1) 10 mg/ml 1
MOG 7 F/67 NMOSD 5120 5120 5120 + + + 1 mg/ml 1.5 (0–2) 10 mg/ml 1
MOG 8 F/5 MDEM 640 1280 640 + + + 1 mg/ml 0 (0–1) n.a. n.a.
MOG 9 F/15 ADEM 320 160 640 + + + 1 mg/ml 0 (0–1) n.a. n.a.
MOG 10 M/13 ADEM 2560 2560 2560 + + + 1 mg/ml 0 (0) n.a. n.a.
MOG 11 F/18 NMOSD 2660 0 1280 + + − n.a. n.a. 10 mg/ml 1
Ctrl 1 M/5 CIS-LETM 0 0 0 − − − 1 mg/ml 0 (0–1) n.a. n.a.
Ctrl 2 M/10 ADEM 0 0 0 − − + 1 mg/ml 0 (0–1) n.a. n.a.
Ctrl 3 F/18 MS 0 0 0 − − − 1 mg/ml 0 (0) n.a. n.a.
Ctrl 4 M/8 ADEM 0 0 0 − − − n.a. n.a. 10 mg/ml 1
HC 1 F/22 HC 0 0 0 − − − 1 mg/ml 0 (0–1) n.a. n.a.
HC 2 M/27 HC 0 0 0 − − − 1 mg/ml 0 (0) n.a. n.a.
HC 3 F/27 HC 0 0 0 − − − 1 mg/ml 0 (0–1) n.a. n.a.
h8-18-C5 > 40,960 > 40,960 > 40,960 + + + 10 μg/ml 3 (2–3) n.a. n.a.
m8-18-C5 > 40,960 > 40,960 > 40,960 + + + n.a. n.a. 5 mg/ml 4
Subcuvia 0 0 0 − − − n.a. n.a. 10 mg/ml 1
PBS 0 0 0 − − − − 0 (0–1) n.a. n.a.
All samples were tested for MOG antibody reactivity on a live cell-based assay (CBA) and on human rat and mouse brain tissue. Slice cultures were evaluated with
a median myelin score (MMS) ranging from 0 to 3 (0 = healthy myelin with well-preserved myelin sheath around myelinated axons, 1 = slight MBP degradation
and myelin disruption, 2 = partial myelin loss, intermediate to severe MBP damage, 3 = almost complete loss of myelin along myelinated axons and severe MBP
loss). Demyelination in the rat EAE model was evaluated with a median demyelination score (DMS) ranging from 0 to 4 (0 = no lesions/slice, 1 = one minor lesion/
slice, 0.05–0.2 mm diameter, 2 = two minor lesions/slice or one medium lesion, > 0.2 mm diameter, 3 = two or more medium lesions/slice, 4 = significant loss of myelin)
Abbreviations: MOG 1-11 MOG antibody-positive patients, Ctrl 1-4 MOG antibody-negative patients, HC 1-3 healthy controls, Subcuvia normal human serum, h8-18-
C5 humanized 8-18-C5 monoclonal MOG antibody, m8-18-C5 mouse 8-18-C5 monoclonal MOG antibody, F female, M male, ADEM acute demyelinating
encephalomyelitis, CIS-LETM clinically isolated syndrome longitudinally extensive transverse myelitis, MDEM multiphasic demyelinating encephalomyelitis, NMOSD
neuromyelitis optica spectrum disorders, rec-ON recurrent optic neuritis, MS multiple sclerosis, n.a. not analyzed
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studies with a smaller sample size [40, 41]. Similarly,
only a subset of hMOG autoantibody-positive samples
was reactive on mouse and rat brain tissue. Only 52% of
the mMOG-positive samples but 100% of the rMOG-
positive samples (CBA, cutoff ≥ 1:160) showed a positive
binding pattern to mouse and rat myelin tissue, respect-
ively. In contrast, 88% hMOG-positive samples bound to
human brain sections. Differential binding to mouse, rat
and/or human tissue was strongly influenced by anti-
body titers to mMOG, rMOG, and hMOG. Specificity of
the tissue binding was confirmed by pre-adsorbing
serum samples with MOG-transfected cells. In case of a
positive tissue binding with hMOG-, mMOG-, or
rMOG-negative samples, the staining signal could not
be diminished by pre-adsorption. In these cases, we can-
not differentiate between low-level MOG binding, bind-
ing to alternative myelin antigens, or background signal.
Staining could be produced by MOG antibodies with
epitope specificity to epitopes revealed only after tissue
fixation. Conversely, the loss of myelin staining observed
for a number of hMOG-positive samples is likely due to
the loss of conformational epitopes due to tissue fixation
and dehydration. The presence of autoantibodies to al-
ternative myelin and neuronal targets have been re-
ported in the CSF of MS patients [49, 53], and these
antibodies may contribute to tissue reactivity both in
hMOG-negative and hMOG-positive samples.
The differences in antibody binding to hMOG,
mMOG, and rMOG are surprising considering the ra-
ther small differences in the amino acid sequences of the
three proteins (Additional file 7). A previous study has
already established the importance of the C-C′ loop in
the recognition of human-specific MOG antibody re-
sponses [40] which might also be responsible for the dif-
ferences in antibody recognition seen in our study. In
contrast, antibodies also reactive with mMOG and prob-
ably also rMOG mainly recognize the F-G loop, which is
also the epitope recognized by the monoclonal antibody
8-18-C5. Further, it is still unknown whether there are
differences in the affinity of human antibodies to differ-
ent MOG epitopes. Whereas it is well known that the af-
finity of the monoclonal antibody 8-18-C5 is higher than
that of other murine MOG antibodies [31], the affinity
of human MOG antibodies has not yet been analyzed
because human monoclonal MOG antibodies needed for
methodological reasons are not available yet.
Serum IgG from only one adult NMOSD patient with
high titers to mMOG, rMOG, and hMOG caused obvi-
ous myelin loss as evidenced by MBP degradation and
signs of axonal disturbances and swellings. Interestingly,
this patient had the highest titer anti-MOG IgG of sub-
class 3 (Additional file 5). Demyelinating effects were
only shown by the addition of human complement and
could not be replicated without complement. This rare
pathology contrasts with other patient samples as well
as previous studies that showed minimal complement-
mediated pathology using human MOG autoantibodies
[38, 39]. Weak complement activation has also been ob-
served in a relapsing encephalomyelitis patient positive
for MOG antibodies with complement activation only
present at areas of active demyelination [17]. These
studies showed that MOG IgG are only to some extent
able to activate the complement pathway and therefore
mediating pathologic effects; however, our study revealed
a major contribution of complement-mediated pathology
in this sample, which is in line with several reports ob-
serving complement deposition in brain tissue of pa-
tients with MOG antibodies [18–20]. Furthermore, this
single MOG-IgG-positive patient may target a specific
epitope that allows efficient complement activation.
Fig. 3 Murine organotypic brain slices incubated with human monoclonal 8-18-C5 with (+ hComp) and without (− hComp) human complement.
Cerebellar folia of proteolipid protein (PLP)-EGFP transgenic mice are stained for neurofilament-heavy (NF-H, blue) and myelin basic protein (MBP;
red). Confocal images were taken with ×25 objectives
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Although we cannot completely exclude whether add-
itional autoantibodies in this sample are responsible
for the observed pathology, pre-adsorption with
hMOG lead to significant reduction of myelin stain-
ing, indicating minimal contribution of other auto-
antibodies against myelin.
While antibodies to MOG are mainly from the IgG1
subtype and therefore able to activate complement in vitro
[31, 54] and in vivo [31], the observed effects of hMOG
autoantibodies are typically minimal and reversible [38,
39]. Two further antibody injection experiments in ro-
dents did not lead to pathogenic effects in connection
with human IgG positive to MOG (A. Saiz, personal com-
munication). In contrast, the monoclonal MOG antibody
8-18-C5 causes severe demyelinated areas in the
organotypic brain model [55]. Hence, it appears that
MOG antibody-mediated effects in ex vivo mouse models
are strongly dependent on high titers to rodent MOG and
the high affinity recognition of specific MOG epitopes that
facilitate complement activation. Importantly, a recent
study has demonstrated that two samples reactive with ro-
dent MOG were able to induce ADCC and CDC in MOG
and MBP EAE after injection in the cerebrospinal fluid
(Edgar Meinl, personal communication).
In a next step, we were interested whether the anti-
MOG antibodies demyelinating in vitro could also cause
demyelination in vivo, by antibody-transfer in MBP-
specific T cell-induced EAE. This model has already
proven to be a suitable animal model to analyze human
autoantibody-mediated effects in vivo [28, 56]. In this
Fig. 4 One of 10 human MOG antibody samples causes mild demyelination in murine cerebellar slice culture. Murine organotypic brain slices
incubated with total IgG purified from MOG-positive (MOG pos.) and MOG-negative (MOG neg.) human sera with human complement (+hComp)
were stained for neurofilament-heavy (NF-H; blue), calbindin (blue), and myelin basic protein (MBP; red). Mild loss of MBP was observed only in
the presence of MOG pos. serum (MOG 7) and hComp. Confocal images were taken with ×25 objectives and ×3 digital zoom for higher magnifications
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context, adoptive transfer of MBP-specific T cells trigger
cellular and humoral CNS autoimmunity by activating
the complement machinery and Fc gamma III receptor-
positive cells, thereby boosting ADCC- and CDC-
mediated lesions in an γ-IFN dependent way in Lewis
rats [52]. However, none of the hMOG-positive samples
showed any pathological effects in the EAE model, in-
cluding sample MOG 7 which was reactive to rMOG
and caused demyelination in murine organotypic brain
culture. One potential explanation for this discrepancy
could be low antibody binding affinity in the in vivo rat
EAE model. Since antibody titers in rat serum to hMOG
and rMOG were relatively low compared to the titers
seen in the patients, the concentration of MOG anti-
bodies may have been insufficient to induce pathologic
effects. To account for the possibility of an insufficient
concentration of antibodies, we also employed a fourfold
higher amount of h/rMOG-positive IgG (40 mg); how-
ever, we did not observe an increase in demyelination.
Similar to the results observed in cerebellar slice cul-
tures, the monoclonal MOG antibody 8-18-C5 applied
in milligram amounts led to substantial myelin loss,
macrophage activation, and complement deposition.
In addition to CDC and ADCC, human MOG anti-
bodies have recently been shown to trigger disease sever-
ity in an EAE model due to the activation of MOG-
specific T cells by fostering autoantigen recognition via
antigen-presenting cells. MOG antibody-mediated de-
myelination was not observed in these studies [36, 37].
Thus, hMOG antibody-mediated CDC may not play a
significant role in this rodent model. To conclude, the
important question whether human MOG antibodies are
pathogenic in vivo is still unsolved. Since the
complement-mediated demyelination is difficult to study
Fig. 5 Spinal cord sections of MBP-T cell EAE animals co-injected with patient antibodies. Patient IgG was reactive to either human, rat, and
mouse MOG (h/r/mMOG pos., MOG 7); human and mouse MOG (h/mMOG pos., MOG 6); or negative to human MOG (hMOG neg.) tested by CBA
KL, Kluver-Barrera (myelin); MOG, myelin oligodendrocyte glycoprotein; ED1, macrophages; CD3, T cells; C9, complement. Spinal cord slices were
digitally magnified at 3.8× and highlighted sections at ×20
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in mice [57], a human MOG transgenic rat model might
be needed to analyze effector mechanisms of human
MOG antibodies. This would be also very important be-
cause cross-reactivity to rodent MOG is not necessarily
related with pathogenicity per se. We still cannot ex-
clude, whether MOG antibodies solely reactive to hu-
man MOG could also induce demyelination in an
animal model more resembling the human species.
However, this study showed that cross-reactivity to ro-
dent MOG is a very important factor to analyze poten-
tial MOG antibody-mediated effector mechanisms in
rodent models.
Our study has several limitations. First, the majority of
patients were children, and most of them had a benign
monophasic disease course. Only very few adult patients
with severe disease courses were included. Indeed, the
only sample able to induce pathogenic effects in the
organotypic brain slice model was from an adult patient.
Second, the purification and injection of total patient
IgG may have resulted in insufficient MOG-IgG concen-
tration to induce pathological effects ex vivo and in vivo.
One possible approach to circumvent problems with
minor antibody concentrations is to directly inject those
antibodies intrathecally or intracerebrally. High efficacy
has been shown recently, by injecting low doses of 8-18-
C5 and complement into the corpus callosum of mice
leading to complement-dependent demyelination [58].
Third, as already mentioned above, cross-reactivity to
rodent MOG is not necessarily related with pathogen-
icity in rodents per se and the pathogenic epitope might
only be present in human MOG. Forth, we cannot to-
tally exclude, whether additional autoantibodies may
contribute to pathology in MOG-seropositive diseases.
Future studies may require purified MOG autoanti-
bodies or recombinant antibodies derived from MOG-
reactive human plasma cells. Finally, only a subset of
samples could be analyzed for the in vivo pathology due
to limited amounts of patient material.
Conclusion
Only a small proportion of antibodies to hMOG are re-
active to rodent MOG as analyzed by CBA and tissue
IHC. While MOG mAb 8-18-C5 caused vigorous
complement-mediated demyelination ex vivo and in
vivo, serum IgG from only a single MOG-seropositive
patient with high-titer antibodies to mMOG and rMOG
was able to induce complement-dependent tissue injury
in an ex vivo organotypic brain slice model. The results
suggest that high-titer species-specific MOG autoanti-
bodies recognizing unique epitopes on native MOG may
be mandatory for CDC in vivo. Future studies should
therefore use hMOG antibody-positive samples with
high titers and affinity to rodent MOG epitopes or
monoclonal MOG antibodies with defined epitope rec-
ognition and affinity before testing them in vivo for
pathogenic potential.
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